IPHANasdaq

Innate Pharma S.A.

Healthcare·Oncology·Phase 2·Marseille, France
OncologyDermatology

Innate Pharma S.A. (IPHA): 4 pipeline candidates · ~2 mo cash runway · 5 clinical trials. Updated within the last hour.

5.9/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.5

1.9 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Innate Pharma S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$167.1M

Cash

$28.1M

Quarterly Burn

$52.8M

Runway

1.9 mo

Revenue

$9.0M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (4 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

6

Total value held

$130K

HolderSharesValue
morgan stanley43,524$56K
jane street group, llc43,365$56K
millennium management llc10,064$13K
rhumbline advisers4,734$6K
gamma investing llc240$307
farther finance advisors, llc10$14
5 clinical trials·CEO: Mr. Jonathan E. Dickinson B.Sc., M.B.A.

Frequently asked questions

How many drug candidates are in Innate Pharma S.A.'s pipeline?

Innate Pharma S.A. (IPHA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Innate Pharma S.A.'s lead drug candidate?

Innate Pharma S.A.'s most advanced tracked candidate is iph2101 (Phase 2) for Smoldering Multiple Myeloma.

What is Innate Pharma S.A.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Innate Pharma S.A. has approximately 1.9 months of cash runway.

What is Innate Pharma S.A.'s market capitalization?

Innate Pharma S.A.'s market capitalization is approximately $167.1M.

Who is the CEO of Innate Pharma S.A.?

Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma S.A. (IPHA).

Get the full picture on Innate Pharma S.A.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.